Xournals

Academic Journal of Modern Applied Sciences

ISSN UA | Volume 01 | Issue 01 | January-2019

The Use Antiepileptic Drug (AED) during Pregnancy

Surya Kiran Sharma[1]

Available online at: www.xournals.com

Received 4th September 2018 | Revised 11th October 2018 | Accepted 14th December 2018

Abstract:

In the world, Epilepsy is known as the communal severe disorder related with neurological factors. Women with epilepsy i.e. WWE understanding numerous physical and social problem related with gender. At the time of pregnancy, the chief concerns linked with epilepsy that contains fetal and maternal threat from abandoned attacks, and damaging effects of handling on the growth of young ones. In pregnant women, increasing the risk of safety whenever an antiepileptic drug is taken by patients but this drug is not totally safe to use in pregnancy as the danger of fetal aberration is improved. Before conception, planning must be done for managing the women's epilepsy during pregnancy. Without medical advice, the existence of an unexpected pregnancy must not be treated with quick alteration or cessation of an antiepileptic drug. In this case, should be used the minimum effective amount of a drug with a small threat of teratogenicity. During pregnancy, doses or amount may require modification as the pharmacokinetics of particular drugs. In this paper, discussed about the using the antiepileptic drug at the time of pregnancy and security of antiepileptic drug use at the time of pregnancy.

Keyword: *Antiepileptic drug, Teratogenicity, Epilepsy, Pregnant women*

Authors:

1. *Indore Nursing College, Dehri Rangwasa, Indore, Madhya Pradesh, INDIA*

Introduction

Epilepsy is considered as communal chronic neurological problem in which, pregnant female have a severe and possibly dangerous condition for both infant as well as mother and essentially used the constant pharmacological medication all over pregnancy. With epilepsy, most pregnant women need to take at least one antiepileptic drug (AED) and this drug is recommended to decrease the seriousness of epilepsy or support to achieve the situations like pain, psychiatric disorders, and migraine. Female compelling AED have a danger of teratogenicity and miscarriage, consisting a 4-8% probability of giving natal to a child having maximum congenital malformation (CM) for the reason that these agents can be removed from placenta to fetus. Teratogenicity of AED was first documentation in the 1960s, in pregnant women with epilepsy, the practice of numerous first-generation AEDs (Valporate) has been studied extensively.

In pregnancy, use of the antiepileptic drug for safety purpose contains the pregnant women in itself condition; the fetus though in her womb, and through its following extra-uterine presence as a newborn. The safety of antiepileptic drugs during pregnancy is not meaningfully diverse from the care of these drug in normal women, except in case of normal women, these drugs are affecting on the pregnant lady and drugs effect on the foetus in utero and afterward. But in current years, antiepileptic drugs have been utilizes in increasingly to treat the illnesses besides epilepsy.

In the United States, around 1.3 million female suffering with epilepsy are in their lively reproductive years and give birth to 25,000 newborns every year. With the favorable outcome, most female having epilepsy will consist an ordinary pregnancy but there are more fetal and maternal danger likened to the overall population. On developing offspring, fall the effects of ADE include both anatomic teratogenic and neurodevelopment significances. Female suffering with epilepsy have offspring on AEDs that are at an major risk for intrauterine growth hindrance, cognitive dysfunction, minor anomalies, major congenital malformations, microcephaly, and infant mortality. “Fetal anticonvulsant syndrome” is consider as something which is utilize to contain various combination of these outcomes.

In pregnant women, treatment of epilepsy by the use of mono-therapy with major effective AED for the women’s epilepsy kind at least effective amount. Valproate drug falls the adverse effect on developing fetus due to which it should be avoided. During pregnancy, epilepsy should be managed by the requirement to weighing the likely serious effects of AEDs on the fetus in contradiction of the effects of attacks on the fetus and mother. During pregnancy, conserving the stability among teratogenic risk and adequate seizure control of ADEs that is a major experiment for neurologists. Over the years, the effectiveness of AEDs may have altered with a better knowledge of their pharmacokinetic properties at the time of pregnancy and their worth in the management of diverse kinds of seizures.

Seizures Control during Pregnancy

In several studies, investigation of pregnancy on the progress of epilepsy from the most of selected professional clinics of epilepsy, possibly consisting a great number of patients with difficult-to-risk disorder of seizure. In which, first check that is present or not, if there seems to be very less or absence of evidence that antiepileptic drug use in pregnancy produces additional security concerns for women tangled and conclusively come from reduced control of her epileptic seizures. Since 1857, effective antiepileptic drug treatment has been obtainable and for many years, it has been little published on untreated epilepsy in pregnancy.

In case of during lack of governing epileptic seizures, possibly will reveal the women who is pregnant to the threat of physical injury and potential death at the time of seizures. Seizures should be controlled during second and third trimester as associated to the first trimester. With epilepsy, loss of seizure control could principal to psychological damage to the woman in addition to physical injury that may result in decreased social activities and chances and may harm her life quality. A number of studies have to show since the mid-1970s that as pregnancy developments, steady-state plasma applications of antiepileptic drugs incline to drop except the drug doses are improved. Involved may factor in producing this fall appear to be:

- The unmetabolized drug’s increasing the renal clearances for the reason that of the physiological growth in glomerular filtration rate that initiates quick in pregnancy which occurrence is of greatest meaning for an antiepileptic drug that undergoes comparatively less or no breakdown in body.

- Growth in biotransformation, for the reason that during pregnancy, improved level of circulating of female steroidal sex hormones that encourage the formation of the cytochrome P (CYP) 450 glucuronosyl transferases and isoenzymes which play the main parts in removing the antiepileptic drug.

- By increasing the motherly extracellular fluid, placental and foetal volumes, womb, due to which effect of dilutional was happen at the time of pregnancy and in late pregnancy, an result balance to an amount when plasma albumin concentration fall, so that there is an increased concentration of unbound i.e. biologically active type of drug that is comparative to the overall drug in plasma.

By these factors, decreases in plasma antiepileptic drug concentration between the individual drug and stage of pregnancy. By renal excretion unmetabolished, reductions incline to be comparatively small for agents that are cleared from body in the main and are bigger for drugs cleared mostly by biotransformation. The control of attack inclines to associate with plasma antiepileptic drug correlations through which it increases the chances of that antiepileptic drug doses amount are used to, dropping circulating applications of antiepileptic drugs in pregnancy may clarify any decline in seizure control that happens. If antiepileptic drug doses are adjusted during and after pregnancy, then clinical impression has been developed, so that maintaining the concentration of plasma drug at their pre-pregnancy standards in the specific, control of seizure is unlikely to decline. In most women, indicated the pregnancy does not look as if to effect the control of seizure by various studies. In seizure control, female who acknowledged modifications can be divided into two around equally sized groups, the first one is improvement and second is deterioration.

Deficiency of vitamin K in Foetus

In the first couple of neonatal days in babies, bleeding diathesis was manifested and who had been unprotected at the time of pregnancy to antiepileptic drugs like phenobarbitone and phenytoin. CYP450 isoenzymes have induced these drugs and supposed that this initiation showed the enlarged metabolic inactivation of vitamin K, conclusively in impaired vitamin K-catalyzed creation of factors of blood coagulation. Vitamin K should be given in more or less amount to female with an antiepileptic drug that is preserved as disorder of seizure during childbirth and it is given to the neonates immediately after birth. This phenomenon may have been prevented from a drug associated bleeding problem. According to recent research, growing extra of these older antiepileptic proxies with more presented non-inducing drugs such as vitamin K, it may cease to any issue during pregnancy but vitamin may be administrated to neonates when designated.

According to National Health and Medical Research Council Guidelines (2000), at the time of birth all the babies are given 1mg intramuscular vitamin K_1 or a sequence of oral vitamin K_1 and motherly should be taken 10mg/day oral vitamin K_1 for one prepartum and when enzyme-encouraging antiepileptic drugs are suggested for the reason that these drugs are predisposed the baby to a type of hemorrhagic to newborn.

Pharmacokinetic (PK) factors

During the gestation period, a series of physiology variations may change the pharmacokinetic (PK) of AEDs. By increasing the volume of plasma and whole water of body that mainly increased volume of dispersal and thus decrease AED serum concentration. Serum albumin concentration may also reduce by increasing plasma volume which may disturb AED plasma clearance and binding of protein. With the development of flow of renal blood and rate of glomerular filtration, may decrease the concentration of serum of AEDs mainly removed with the help of kidneys. The other relevant factors may hamper the PK of AED which are not as much of well documented like altered biotransformation capacity and alterations in absorption of gastrointestinal motility/drug. The concentration of serum affected by a huge number of issues, as well as the noticeable inter-individual changes both in drug disposition and seizure control, make clinical reality no matter what else than modest. In the case of pregnancy, PK of antiepileptic drugs may alter and amount of doses have to stable the threat of seizures with decreasing the threat of fetus harming.

Valproate (VPA)

Substantial danger of maximum abnormalities has to be seen in four pregnancy and numerous smaller studies that containing spina bifida when valproate is consider as monotherapy or with further drugs. After delivery, overall VPA concentration of serum may

deteriorate by 50% and growth to levels of pre-pregnancy contained by each week. In serum albumin concentrations, VPA is extremely bound of protein and later vulnerable to reduction of pregnancy-induced. Therefore, the liberated segment has been revealed to be in reverse connected to concentration of serum albumin. It is a pharmacologically active and free fraction of a drug, this might balance the decline in overall concentration of VPA serum. With increasingly total VPA serum concentrations, then increasing free fraction over-proportionally. Nine pregnancies a reduction of 39% of overall levels was observed, while boundless levels maximize by 25% at the time of delivery. The growth in dose had considered in 4 of the patients. Teratogenesis disease has been reduced in case of valproate dose that reduces to least during pregnancy, the prepartum actual dose may require to be re-established previously the beginning of labor.

Lamotrigine (LTG)

LTG has a comparatively less amount of linking of protein i.e. 55% and is not likely to be meaningfully exaggerated by alteration concentration of serum albumin. Though, LTG is widely absorbed, mostly to LTG-N2- glucuronide by uridine-diphosphate glucuronosyltransferase (UGT). In the previous trimester of pregnancy, its apparent clearance that growths to at minimum the double likened to baseline, by 40-60% serum concentration of dose-normalized may be decrease in third trimester, recurring to levels of non-pregnant inside 1—2 weeks of postpartum. When LTG serum concentrations fall then effect is less marked in female on inhibiting co-medication or enzyme-inducing, mentioning an improved rate of glucuronidation as the underlying mechanism. During pregnancy, an enlarged LTG-N2-glucuronide/LTG serum absorption percentage has currently been established. In the first trimester of pregnancy, exposure to lamotrigine may occur an improved risk of oral clefts.

Carbamazepine (CBZ)

According to the extent study, carbamazepine increased with a threat of structural birth defects containing spina bifida. In the third trimester, plasma clearance upsurges at the time of pregnancy with extreme and binding the protein i.e. 70%. Its serum concentration may decline by over 40, but in the case of an unbound drug, it may be less affected. CBZ has a pharmacologically active metabolite, carbamazepine-10, 11-epoxide. During pregnancy, the ratio of epoxide metabolite to CBZ serum concentrations typically maximized. Although not in a predictable manner.

Phenytoin (PHT)

With epilepsy, PHT is used less frequently in women and produce an increase in major malformations. With a decrease in concentration of plasma and possible harm of control of seizure, a noticeable growth in the clearance of phenytoin in pregnancy. When a higher dose is required is to determine the regular monitoring of plasma concentrations throughout pregnancy. Prevent phenytoin toxicity with the help of monitoring the postpartum. From the initial stage of pregnancy, PHT serum levels reduces and may drop by more than 60% in the third trimester and returning to previous level of pregnancy in the interior few weeks once the delivery is done. Still, a precise relation among overall serum levels and control of seizure of PHT has not been recognized and this may be connected to alter in its free fraction. It is extremely protein-bound, which make it vulnerable to change in concentration of plasma.

Phenobarbital (PB)

Phenobarbital serum stages reduced at the time of pregnancy. According to this paper, overall concentration of total serum dropped by 55% with the harshest decrease at the time of first trimester. The uncontrolled levels were a decline in the case of protein binding that is relatively low but substantial inter-individual differences have been established.

Levetiracetam (LEV)

During pregnancy, LEV drug has been used and its teratogenic threat is unidentified and it seems to be a substantial growth in approval and a connected drop of concentration of blood. If this is associated with a damage of control of epilepsy, it is not yet recognized. Serum observing is not presently existing, but may show helpful in clinical training. In blood, one-third of an oral amount of dose is processed by hydrolysis and in urine, two-thirds are commonly observed unaffected. The fundamental mechanism is unknown. Hence, both developed the renal blood and/or increased peripheral hydrolysis movement are potential in use.

Topiramate (TPM)

TPM is metabolized in small proportion and around 40% of an oral amount of dose is removed unaffected by the kidney. Therefore, a growth in pregnancy-connected flow of renal blood influence mainly to an improved renal approval and a failure in serum concentration of TPM.

Oxcarbazepine (OXC)

OXC is rapidly metabolized to the pharmacologically active, monohydroxycarbazepine (MHD-OXC) after oral intake, which is reduced as a glucuronide. The binding of protein of MHD-OXC is lesser than 50%. During pregnancy, this serum concentration of MHD was around 36% lower, associated to post-pregnancy and pre-pregnancy morals.

Pregabalin (PGB) and Gabapentin (GBP)

Through the kidneys, PGB and GBP are not metabolized and are removed unaffected. Supposedly, an enlarged rate of glomerular filtration may then lead to decreased concentration of serum.

Zonisamide (ZNS)

ZNS is considered 60% protein-bound and suffers wide biotransformation. Increased glomerular filtration and decreased serum albumin concentrations degree would not be probable to encourage the affected alteration in the PK of ZNS. The improved volume of dispersal is the other pregnancy-related alteration that might affect the serum concentration of ZNS.

Newer AEDs

In the different generation of AEDs, contains large amount of basically varied combinations that may have to demonstrate effects as teratogenic in the case of preclinical animal research. None of the causes has been appropriately verified through the human pregnancy with the potential allowance of LTG and evaluate teratogenicity or safety. Conferring to this study, the current research from LTG pregnancy registry is dependent on 414 first-trimester monotherapy experiences and its deformities rate was 2.9%. Comprised all mutual category of AED in described deficiencies of birth defects and were not of a consistent pattern.

Review of Literature

Kulaga et.al 2011, stated that 0.28% of pregnant women use AED at the time of pregnancy. Most of women with epilepsy, taken the mono-therapy at the time of pregnancy suggested that there is credit of the significance of both fetus and mother of constant govern of symptoms of epilepsy at the time of gestation. Preceding to pregnancy, 12% of female treated through epilepsy and not acceptance the AEDs at the time of gestation periods. With the gestation period, if pregnant lady used an AED polytherapy treatment, then it is more likely to be wellbeing recipients or attends neurologist visits more normally in the 12-month period previous to the initial day of gestation than those on AED monotherapy or no therapy. During pregnancy, carabamazapine has been revealed to be a reasonably safer point for govern of epileptic attacks. If the first trimester of pregnancy used the valproate shown to hold teratogenic.

Widnes, Schjøtt and Granas 2012, dictated that to avoid seizures, pregnant women with epilepsy (WWE) were using confidently AEDs, while dose adjustments linked with pregnancy enlarged perceived threats of seizures or teratogenicity. The women were satisfied with follow-up the medicine and treatment that are provided by physicians and neurologist. It has some strategies that may also be applicable for medicines material to pregnant having chronic diseases that deliver stable appearances of both threat and benefits both of AEDs and other drugs to attain acceptable health of fetus as well as mother.

Díaz et.al 2012, in this study, the threat of abnormalities complete linked with first-trimester introduction to specific AEDs that have reached from 9.3% for valproate to 2.0% for lamotrigine. According to phenobarbital, valproate and topiramate users, the danger of oral breaks was further 10 per 1,000 for infants uncovered, which is developed than expected dependent on any mention population (approximately 1 per 1,000 births). The teratogenicity of valproic acid is well recognized. The first-trimester contact to valproic acid upsurges the threat of neural tube defects from approximately 1 per 1,000 to 10 per 1,000 births. Oral clefts, cardiovascular and urogenital faults are connected with phenobarbital and these failings have also been stated after phenytoin therapy.

Clemow et.al 2014, dictated that in pregnancy, influences chiefly to a absence of data-supported result production on medicine utilizes comprised restricted research methods, boundaries of research standards, recent research methodologies,

fragmentation of current data, lack of data, poor patient communication and inconsistent application of findings to clinical practice. The threat-based methods that do not reflect the welfares of action and process concerns are social factors that also prevent the facility of proper medical direction.

Bech et.al 2014, in this paper, no increasing the risk of spontaneous abortion during pregnancy when female having epilepsy who take antiepileptic drugs. According to data, the risk of fatal death is low in pregnant having epilepsy can come to an end treatment of antiepileptic drug. This work specified that female suffering with epilepsy preserved with a heavy dose of an antiepileptic drug that strength have an increased threat of natural abortion, especially when using high doses of clonazepam, carbamazepine, and valproate. This drug is harmful effects on emerging fetus comprising inherited abnormalities and severe effects on neurodevelopment.

Pem, Gupta and Khatik 2016, concluded that safe and unsafe medications during pregnancy are very important prospective of life as it carries the two lives conjoined for the certain period of time. Both mother and fetus should be safe, sound and grow healthy during that time period. It is very important for the one to be aware of the contraindications with the new discovery of the drugs during undergoing any medications. Majority of pregnant women that would not take a drug treatment as prescribed by a physician and neurologist as there is the same fear of harming the fetus as the main concern for mothers. It is important that risk and benefits of stopping treatment to be explained and informed properly.

Veroniki et.al 2017, stated that this examination suggested that the recent generations of lamotrigine, AEDs, and levetiracetam, were not related with statistically important growth threat to congenital malformations likened to control and less likely to link with children experience cardiac abnormalities than regulator. Increasing the threat of deformities for topiramate, phenobarbital, valproate, phenytoin, ethosuximide, and carbamazepine.

Ferri et.al 2018, stated that with generalized epilepsy and focal epilepsy, the percentage of patients are comparable in both periods examined and reliable with the proportions observed in the EURAP registry. This work appear alteration in pattern of treatment of LTG, with less patients with generalized epilepsy receiving the drug in the more current period that in the first. This type of drug is not effective for generalized myoclonic epilepsy. According to Australian registry, AEDs re more actual for handling epilepsy in pregnant than the fresh AEDs (TPM, LTG, and LEV) in the entire sequence as well as in the collection of patients preserved meanwhile 2008. This work also discovered that reduce in the usage of CBZ and a smaller amount to VPA and utilizes of LEV improved knowingly.

Conclusion

Antiepileptic drug plays an important role with women epilepsy because when these drugs are received by pregnant women, it is a better than 90% chance that the child will be normal. But females having epilepsy have developed threat for fetal and maternal implications, these risk can be significantly reduced by the range of AED treatment routines. The most effective drug is valproate that reduced the risk of epilepsy and therapeutic dilemma. Without complication, most infants whose mothers are taking the antiepileptic drugs can be successfully breastfed. The highly protein destined and boundless concentrations may be least affected than overall levels.

References:

Bech, B.h., et al. "Use of Antiepileptic Drugs During Pregnancy and Risk of Spontaneous Abortion and Stillbirth." *Obstetric Anesthesia Digest*, vol. 35, no. 3, 2015, p. 139., doi:10.1097/01.aoa.0000469474.65223.81.

Brodtkorb, Eylert, and Arne Reimers. "Seizure Control and Pharmacokinetics of Antiepileptic Drugs in Pregnant Women with Epilepsy." *Seizure*, vol. 17, no. 2, 2008, pp. 160–165., doi:10.1016/j.seizure.2007.11.015.

Clemow, David B., et al. "Clinical Data for Informed Medication Use in Pregnancy." *Therapeutic Innovation & Regulatory Science*, vol. 48, no. 2, 2014, pp. 134–144., doi:10.1177/2168479014523006.

Davanzo,, Riccardo, et al. "Antiepileptic Drugs and Breastfeeding." *Italian Journal of Pediatrics*, vol. 39, Aug. 2013, pp. 1–11.

Eadie, Mervyn J. "Antiepileptic Drug Safety in Pregnancy: Possible Dangers for the Pregnant Woman and Her Foetus." *The Pharmaceutical Journal: A Royal Pharmaceutical Society Publication*, 15 Jan. 2016.

Ferri, M. Martinez, et al. "Comparative Study of Antiepileptic Drug Use during Pregnancy over a Period of 12 Years in Spain. Efficacy of the Newer Antiepileptic Drugs Lamotrigine, Levetiracetam, and Oxcarbazepine." *Neurología (English Edition)*, vol. 33, no. 2, 2018, pp. 78–84., doi:10.1016/j.nrleng.2016.05.008.

Hernandez-Diaz, S., et al. "Comparative Safety of Antiepileptic Drugs during Pregnancy." *Neurology*, vol. 78, no. 21, Feb. 2012, pp. 1692–1699., doi:10.1212/wnl.0b013e3182574f39.

Kulaga, Sophie, et al. "Antiepileptic Drug Use during Pregnancy: Perinatal Outcomes." *Seizure*, vol. 20, no. 9, 2011, pp. 667–672., doi:10.1016/j.seizure.2011.06.012.

Lander, Cecilie M. "Antiepileptic Drugs in Pregnancy and Lactation." *Australian Prescriber* , vol. 31, no. 3, June 2008, pp. 70–72.

Pem, Tshering, et al. "Safe and Unsafe Drugs during Pregnancy." *Journal of Chemical and Pharmaceutical Research*, vol. 8, no. 3, 2016, pp. 652–663.

Pennell, Page B. "Antiepileptic Drugs during Pregnancy: What Is Known and Which AEDs Seem to Be Safest?" *Epilepsia*, vol. 49, 2008, pp. 43–55., doi:10.1111/j.1528-1167.2008.01926.x.

Pennell, Page B. "Using Current Evidence in Selecting Antiepileptic Drugs for Use during Pregnancy." *Epilepsy Currents*, vol. 5, no. 2, 2005, pp. 45–51., doi:10.1111/j.1535-7597.2005.05201.x.

Thomas SV. "Management of Epilepsy and Pregnancy." *J Postgrad Med*, vol. 52, no. 1, Mar. 2006, pp. 58–64.

Veroniki, Areti Angeliki, et al. "Comparative Safety of Anti-Epileptic Drugs during Pregnancy: a Systematic Review and Network Meta-Analysis of Congenital Malformations and Prenatal Outcomes." *BMC Medicine*, vol. 15, no. 1, May 2017, doi:10.1186/s12916-017-0845-1.

Widnes, Sofia Frost, et al. "Risk Perception and Medicines Information Needs in Pregnant Women with Epilepsy – A Qualitative Study." *Seizure*, vol. 21, no. 8, 2012, pp. 597–602., doi:10.1016/j.seizure.2012.06.007.